Entrada Therapeutics, Inc.
Clinical trials sponsored by Entrada Therapeutics, Inc., explained in plain language.
-
New hope for boys with devastating muscle disease
Disease control Recruiting nowThis study is testing a new drug called ENTR-601-44 for Duchenne muscular dystrophy (DMD), a severe genetic muscle-wasting disease. It aims to see if the drug is safe, find the right dose, and check if it helps produce a needed muscle protein. The trial is for boys and young men …
Phase: PHASE1, PHASE2 • Sponsor: Entrada Therapeutics, Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New hope for DMD: experimental drug aims to restore muscle protein
Disease control Recruiting nowThis study is testing a new medicine called ENTR-601-45 for boys and young men with Duchenne muscular dystrophy (DMD), a rare muscle-wasting disease. The first part checks the medicine's safety and finds the best dose, while the second part looks at how well it works. Researchers…
Phase: PHASE1, PHASE2 • Sponsor: Entrada Therapeutics, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC